title: Novel therapies for chronic myelogenous leukemia.
abstract: The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation. We have systematically reviewed each of these novel therapeutic approaches in this article.
authors.affiliation: Stem Cell Institute, Division of Hematology-Oncology and Transplantation, University of Minnesota, Minneapolis, Minn 55455, USA.
authors.forename: B N
authors.initials: BN
authors.lastname: Jahagirdar
authors.forename: J S
authors.initials: JS
authors.lastname: Miller
authors.forename: A
authors.initials: A
authors.lastname: Shet
authors.forename: C M
authors.initials: CM
authors.lastname: Verfaillie
mesh_terms: D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D051231:Farnesyltranstransferase; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D020570:Genes, myb; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D016219:Immunotherapy, Adoptive; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D008727:Methotrexate / Q000494:pharmacology; D008954:Models, Biological; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D012333:RNA, Messenger / Q000037:antagonists & inhibitors; D012334:RNA, Neoplasm / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000068877:Imatinib Mesylate; D013762:Tetrahydrofolate Dehydrogenase; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D016044:Fusion Proteins, bcr-abl; D008727:Methotrexate